Home / Knowledge Centre /
Publication

Identification and Validation of an Anthracycline / Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer

There is no method routinely used to predict response to anthracycline and cyclophosphamide–based chemotherapy in the clinic; therefore patients often receive treatment for breast cancer with no benefit. Loss of the Fanconi anemia/BRCA (FA/BRCA) DNA damage response (DDR) pathway occurs in approximately 25% of breast cancer patients through several mechanisms and results in sensitisation to DNA-damaging agents. The aim of this study was to develop an assay to detect DDR-deficient tumors associated with loss of the FA/BRCA pathway, for the purpose of treatment selection.

View Resource

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies